William Go, M.D., Ph.D.

Chief Medical Officer

Prior to joining Janux, Will served as Chief Medical Officer at A2 Biotherapeutics, where he led development of logic-gated CAR T-cell therapies for solid tumors. During his tenure, A2 Bio initiated three Phase 1 clinical trials across multiple solid tumor indications. Prior to that, Will held senior leadership roles at Kite Pharma, where he led the pivotal ZUMA-1 trial supporting the FDA and EMA approvals of YESCARTA^®, the first CAR T-cell therapy approved for large B-cell lymphoma. Following Kite’s acquisition by Gilead Sciences, he continued in a senior clinical development leadership role overseeing programs in large B-cell lymphoma.

Earlier in his career at Amgen, Will contributed to the global label expansion of Vectibix^® and helped advance extended RAS next-generation sequencing strategies in colorectal cancer to identify predictive biomarkers.

Will earned a B.A. in Biology from Carleton College and completed an M.D. and Ph.D. through the UC San Diego Medical Scientist Training Program. He completed residency training in internal medicine and a fellowship in hematology/oncology at UC San Diego, with tumor immunology research supported by fellowships from the California Institute for Regenerative Medicine and the American Association of Cancer Institutes.